Pharsight

Canasa generic

Canasa is an anti-inflammatory drug owned by Allergan and contains the active ingredient mesalamine. The drug was first authorized for market use on January 5, 2001.

When will Canasa generic be available?

Canasa has 2 drug patents, both set to expire on June 6, 2028; hence, the generics of Canasa can potentially be available after that date. These patents safeguard the formulation method of the Mesalamine suppository.

Canasa uses

Canasa, which is available in suppository form for rectal administration, is primarily used for treating ulcerative proctitis, a type of inflammatory bowel disease. Its active ingredient, mesalamine, helps decrease inflammation in the rectum, alleviating symptoms like stomach pain, rectal bleeding, and diarrhea.

Canasa patent expiration

Canasa has two significant patents, titled 'Mesalamine suppository,' both due to expire on June 6, 2028, which will likely make way for Canasa generic versions. Below are the details of the patent:

Canasa dosage

Want to ask something?